article · Tropical Journal of Pharmaceutical Research
Neglected tropical diseases (NTDs), such as Leishmaniasis, Chagas’ disease, and trypanosomiasis affect billions of people worldwide, particularly in low-income regions, and pose significant public health challenges. Emerging evidence suggests that gut microbiota play a crucial role in modulating immune responses to these infections, influencing disease progression and host defence mechanisms. This review examines the interplay between gut microbiota and the immune system in the context of NTDs, highlighting mechanisms such as microbial-mediated immune priming, modulation of inflammation, and interactions with pathogenic organisms. Dysbiosis—an imbalance in gut microbiota—has been implicated in exacerbating NTDs pathogenesis, while microbiome-targeted interventions offer potential therapeutic strategies. A deeper understanding of host-microbiota interactions may facilitate the development of novel approaches to NTDs management, integrating microbiome modulation into existing treatment and preventive frameworks. Further research is necessary to elucidate specific microbial signatures associated with NTDs and their potential for therapeutic exploitation.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.4314/tjpr.v24i9.12
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.